

07-16-01

0590^{#4}

EXPRESS MAIL CERTIFICATE

Date 7/13/01 Label No. 56903059543VS

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

D B Peck

D B Peck
Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100



Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 3380/1I127-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lawrence PAPSIDERO; Lyn DYSTER; Jana FRUSTACI

Serial No.: 09/834,794

Confirmation No.: 1046

Filed: April 13, 2001

For: HUMAN CHEMOKINE AND ITS USE FOR DETECTION
AND TREATMENT OF BREAST DISEASE

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449.

A copy of the claims in the co-pending divisional patent application (U.S. Patent Application Serial No.: 09/834,795; filed April 13, 2001) is

enclosed herewith.

Copies of references not enclosed herewith were previously filed in the allowed parent application (U.S. Patent Application Serial No: 09/146,580; allowed May 30, 2001).

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first action on the merits has been mailed.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of

Serial No. 09/834,794

Docket No. 3380/11127-US4


examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: July 13, 2001


Neepa Y. Choksi, Ph.D.
Registration No. 47,488
Agent for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, NY 10022
(212) 527-7700